FDA Issues Warning About Rare but Serious Liver Injury With the Use of Fezolinetant (VEOZAH) for Hot Flashes Due to Menopause
View all alerts
Worst Pills, Best Pills

An expert, independent second opinion on more than 1,800 prescription drugs, over-the-counter medications, and supplements

mibefradil (POSICOR)


WORST PILLS, BEST PILLS NEWSLETTER ARTICLES

Search results below include Worst Pills, Best Pills Newsletter Articles where your selected drug is a primary subject of discussion.

Update on Withdrawals of Dangerous Drugs in the U.S.
January 2011
This article lists 11 of the prescription drugs that we warned Worst Pills, Best Pills News subscribers not to use before they were banned by the FDA. Subscribers knew an average of 3.3 years before the FDA acted that these medications were unsafe to use.

ADDITIONAL INFORMATION FROM PUBLIC CITIZEN

Search results below include Additional Information from Public Citizen where your selected drug is a primary subject of discussion.

Letter to the Department of Health and Human Services urging that they implement and enforce the Code of Ethics for Government (HRG Publication #1516)
It is urgent for you and other leaders in HHS--and all government agencies--to re-read and strongly urge the implementation and enforcement of a 1958 Congressional Resolution entitled The Code of Ethics for Government Service (175 72 Stat B12, 1958) which states that "Any person in Government Service should put loyalty to the highest moral principles and to country above loyalty to persons, party or Government department."
Letter to the Editor in the Journal of the American Medical Association in response to an article on the safety of Food and Drug Administration approved drugs which were withdrawn (HRG Publication #1502)
Letters-Science by Peter Lurie, M.D., M.P.H. Larry Sasich, Pharm.D., M.P.H. Letter to the Editor in the Journal of the American Medical Association in response to an article on the safety of Food and Drug Administration approved drugs which were withdrawn
Statement about a Food and Drug Adminstration article in the Journal of the American Medical Association regarding recently withdrawn drugs and the safety of newly approved drugs. (HRG Publication #1481)
None of these drugs were breakthrough drugs and the serious safety concerns should have prevented their approval in the cases of Redux, Posicor, and Duract and a much earlier market withdrawal for Seldane. FDA's conclusion that there is no problem associated with these drug safety withdrawals should not be taken seriously because to do so will continue to jeopardize the safety of American patients.
Statement on the withdrawal of mibefradil/Posicor from the market. (HRG Publication #1441)
Mibefradil (Posicor) is an example of the risks that the American public will continue to face in the future because of the flood of new drugs that the FDA has rushed to approve in the last several years.

Show secondary search results for mibefradil (POSICOR)

Disclaimer

The information on this website is not intended to substitute for professional medical advice, diagnosis, or treatment. Consult your doctor before changing or discontinuing any medication.